Quick Answer
Gain Therapeutics, Inc. reported Total Assets of $22.82 million for the year ending 2025.
- Gain Therapeutics, Inc. showed an increase of +88.2% in Total Assets from 2024 to 2025.
- This data is from Gain Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $48.04 million | Q2 2021: $45.35 million | Q3 2021: $42.56 million | Q1 2022: $37.60 million | Q2 2022: $31.89 million | Q3 2022: $28.33 million | Q1 2023: $21.32 million | Q2 2023: $18.26 million | Q3 2023: $14.10 million | Q1 2024: $14.58 million | Q2 2024: $19.20 million | Q3 2024: $14.37 million | Q1 2025: $11.62 million | Q2 2025: $9.83 million | Q3 2025: $10.97 million.
- Over the full 6 years of available data (2020 to 2025), Gain Therapeutics, Inc.'s Total Assets has grown by 137.6%.
- Historical annual values: Fiscal year 2025: $22.82 million | Fiscal year 2024: $12.12 million | Fiscal year 2023: $18.61 million | Fiscal year 2022: $24.10 million | Fiscal year 2021: $38.99 million | Fiscal year 2020: $9.60 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: